RxGen, Inc. Announces The Formation Of RxGen PrimaTox, Inc., A Subsidiary Focused On Molecular Toxicology In Primates And Humans, Spencer Farr Named CEO

SANTA FE, N.M. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Jan. 26, 2006--Today RxGen Inc. announced that it has formed RxGen PrimaTox Inc., a wholly owned subsidiary that is focused on drug safety products and services to improve the preclinical and clinical drug development process. Spencer Farr, Ph.D., the founder of Xenometrix, Inc. and Phase-1 Toxicology, Inc., will serve as RxP’s CEO and Chairman. RxP is leveraging RxGen’s extensive primate research capabilities as well as experience in functional genomics and toxicology to offer integrated panels of proprietary ‘omics’ assays, toxicity biomarkers, and predictive toxicity tests.